Can a pill tame inflammation to protect the heart?
NCT ID NCT07797855
First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time
Summary
This trial tests an experimental medicine called NNC0705-0002 in healthy adults. The drug aims to address conditions where inflammation may contribute to heart and metabolic problems. Researchers will give single and multiple oral doses to about 112 participants, some receiving a placebo, to check safety, tolerability, how the drug moves through the body, and how it is absorbed and eliminated. Participation may last up to about 7 weeks, including screening and follow-up.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- NNC0705-0002, an experimental oral medicine being developed for conditions where inflammation may contribute to heart and metabolic health problems
- What this could lead to
- If this early trial succeeds, NNC0705-0002 could become a new oral treatment for heart and metabolic conditions driven by inflammation.
- What could go wrong
- This is a first-in-human study with a small number of healthy adults, so the drug may not be safe or effective in patients. Side effects are possible, and the results may not predict how the drug works in people with disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 112 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men or women of non-childbearing potential. * Age 18-55 years (both inclusive) at the time of signing the informed consent. * Body mass index (BMI) between 18.5 to 29.9 kilogram per square metre (kg/m\^2) (both inclusive) at screening. * Body weight: greater than or equal to (≥) 50.0 kg at screening. * Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. * Any of the below laboratory safety parameters at screening outside normal range, see designated reference range documents for specific values. * Alanine aminotransferase (ALT) greater than (\>) upper limit of normal (ULN) * Aspartate aminotransferase (AST) \>ULN * Total bilirubin (TBL) \>ULN * Creatinine \>ULN * International normalised ratio (INR) \>ULN * High-sensitivity C-reactive protein (hsCRP) greater than (\>)5 milligram per liter (mg/L) (males) and \>8 mg/L (females) * Use of prescription medicinal products or vaccines within 14 days before dosing and/or non-prescription medicinal products within 7 days before dosing. Exceptions are: Topical medications not reaching systemic circulation; less than once per week of over-the-counter acetaminophen/paracetamol and/or nonsteroidal anti-inflammatory drugs at their labelled doses for mild pain; vitamins at their labelled doses.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiometabolic diseases are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
ICON - location Groningen
Groningen, 9728 NZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pilot study to evaluate the effect of nicotinamide riboside on immune activation in psoriasis
- Comparative effects of three breathing techniques on heart rate variability, attention, reaction time, and anxiety in healthy adults: a randomized controlled trial
- An Open-Label phase 1 study to assess the safety, tolerability, and pharmacokinetics of a single dose of a new tablet formulation of TRTL-729 in healthy adults
- A phase 2b, randomized, placebo-controlled, observer-blind study in adults 60 years of age and older to evaluate the efficacy, safety, and immunogenicity of a bivalent protein vaccine candidate against respiratory syncytial virus (RSV) and human metapneumovirus (HMPV)
- THERMOS-LUNCH: effects of meals differing in nutritional quality and environmental footprint on postprandial metabolism, Diet-Induced thermogenesis, respiratory quotient, satiety, and hydration status in healthy young men
- Phase i clinical study, open-label, randomized, parallel to evaluate the safety of the 200 mg dexibuprofen following single and multiple dose oral administration in healthy participants of both sexes under fasting and fed conditions.